Castle Biosciences (CSTL)
NASDAQ:CSTL
US Market
Holding CSTL?
Track your performance easily

Castle Biosciences (CSTL) Stock Forecast & Price Target

394 Followers
See the Price Targets and Ratings of:

CSTL Analyst Ratings

Strong Buy
6Ratings
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Castle
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CSTL Stock 12 Month Forecast

Average Price Target

$39.17
▲(18.16% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Castle Biosciences in the last 3 months. The average price target is $39.17 with a high forecast of $45.00 and a low forecast of $34.00. The average price target represents a 18.16% change from the last price of $33.15.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","31":"$31","46":"$46","23.5":"$23.5","38.5":"$38.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,23.5,31,38.5,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.67,35.464615384615385,36.25923076923077,37.05384615384615,37.84846153846154,38.643076923076926,39.43769230769231,40.23230769230769,41.026923076923076,41.82153846153846,42.61615384615385,43.41076923076923,44.20538461538462,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.67,35.01615384615385,35.362307692307695,35.70846153846154,36.05461538461539,36.400769230769235,36.74692307692308,37.09307692307692,37.43923076923077,37.785384615384615,38.13153846153846,38.47769230769231,38.823846153846155,{"y":39.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.67,34.61846153846154,34.566923076923075,34.51538461538462,34.463846153846156,34.41230769230769,34.36076923076923,34.30923076923077,34.25769230769231,34.206153846153846,34.15461538461538,34.10307692307693,34.05153846153846,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.98,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.97,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.41,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.94,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.82,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.33,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.15,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.4,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.28,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.32,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.35,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$45.00Average Price Target$39.17Lowest Price Target$34.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
KeyBanc
$25$28
Buy
-15.54%
Downside
Reiterated
03/01/24
Castle Biosciences price target raised to $28 from $25 at KeyBancCastle Biosciences price target raised to $28 from $25 at KeyBanc
Guggenheim Analyst forecast on CSTL
Unknown Analyst
Not Ranked
Guggenheim
$25
Buy
-24.59%
Downside
Initiated
12/14/23
Castle Biosciences initiated with bullish view at Guggenheim, here's whyCastle Biosciences initiated with bullish view at Guggenheim, here's why

Best Analysts Covering Castle Biosciences

Which Analyst Should I Follow If I Want to Buy CSTL and Sell After:
1 Month
xxx
Success Rate
12/16 ratings generated profit
75%
Average Return
+8.09%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +8.09% per trade.
3 Months
xxx
Success Rate
11/16 ratings generated profit
69%
Average Return
+13.68%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +13.68% per trade.
1 Year
Sung Ji NamScotiabank
Success Rate
11/16 ratings generated profit
69%
Average Return
+33.10%
reiterated a buy rating 3 months ago
Copying Sung Ji Nam's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +33.10% per trade.
2 Years
xxx
Success Rate
16/18 ratings generated profit
89%
Average Return
+58.07%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +58.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CSTL Analyst Recommendation Trends

Rating
May 24
Jun 24
Jul 24
Aug 24
Oct 24
Strong Buy
5
5
5
5
4
Buy
6
3
4
6
9
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
8
9
11
13
In the current month, CSTL has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CSTL average Analyst price target in the past 3 months is $39.17.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

CSTL Financial Forecast

CSTL Earnings Forecast

Next quarter’s earnings estimate for CSTL is >-$0.01 with a range of -$0.50 to $0.26. The previous quarter’s EPS was $0.31. CSTL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year CSTL has Outperformed its overall industry.
Next quarter’s earnings estimate for CSTL is >-$0.01 with a range of -$0.50 to $0.26. The previous quarter’s EPS was $0.31. CSTL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year CSTL has Outperformed its overall industry.

CSTL Sales Forecast

Next quarter’s sales forecast for CSTL is $79.85M with a range of $60.10M to $88.00M. The previous quarter’s sales results were $87.00M. CSTL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.42% of the time in the same period. In the last calendar year CSTL has Outperformed its overall industry.
Next quarter’s sales forecast for CSTL is $79.85M with a range of $60.10M to $88.00M. The previous quarter’s sales results were $87.00M. CSTL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.42% of the time in the same period. In the last calendar year CSTL has Outperformed its overall industry.

CSTL Stock Forecast FAQ

What is CSTL’s average 12-month price target, according to analysts?
Based on analyst ratings, Castle Biosciences’s 12-month average price target is $39.17.
    What is CSTL’s upside potential, based on the analysts’ average price target?
    Castle Biosciences has 18.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CSTL a Buy, Sell or Hold?
          Castle Biosciences has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Castle Biosciences’s price target?
            The average price target for Castle Biosciences is $39.17. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $45.00 ,the lowest forecast is $34.00. The average price target represents 18.16% Increase from the current price of $33.15.
              What do analysts say about Castle Biosciences?
              Castle Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of CSTL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis